Chronic illnesses such as cancer and autoimmune disorders significantly strain both patients and healthcare systems. Traditional long-term drug therapies, which often have non-specific effects, can ...

As people grow older, their immune systems do not simply slow down, they often become locked into a simmering, ...

As CRISPR and other gene editing therapies move into clinical trials, an important question remains—are these potentially life-saving treatments safe? Genome editing therapies hold great promise for ...

Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to invest in. On December 8, Sana ...

An experimental gene editing cell therapy for sickle cell disease has shown encouraging early results in a phase 1/phase 2 multicenter clinical trial, according to researchers at Cleveland Clinic ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

At age 45, Dr. Lakiea Bailey said, for the longest time, that she was the oldest person with sickle cell anemia that she knew. The executive director of the nonprofit patient advocacy group the Sickle ...

A breakthrough treatment for sickle cell patients could soon become the first gene-editing treatment to be approved by the Food and Drug Administration (FDA). Sickle cell disease (SCD) is an inherited ...